UA93496C2 - Стерильний склад модифікатора імунної відповіді та способи одержання зазначеного складу - Google Patents

Стерильний склад модифікатора імунної відповіді та способи одержання зазначеного складу

Info

Publication number
UA93496C2
UA93496C2 UAA200708769A UAA200708769A UA93496C2 UA 93496 C2 UA93496 C2 UA 93496C2 UA A200708769 A UAA200708769 A UA A200708769A UA A200708769 A UAA200708769 A UA A200708769A UA 93496 C2 UA93496 C2 UA 93496C2
Authority
UA
Ukraine
Prior art keywords
immune response
response modifier
preparation
modifier compositions
drug compound
Prior art date
Application number
UAA200708769A
Other languages
English (en)
Russian (ru)
Inventor
Д. Стосз Джеймс
С. Стейтем Алексіс
Т. Трунг Майхен
Original Assignee
Меда Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38617896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA93496(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Меда Аб filed Critical Меда Аб
Publication of UA93496C2 publication Critical patent/UA93496C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Винахід стосується фармацевтичної композиції для місцевого застосування, що включає модифікуючу імунну відповідь лікарську сполуку, що стійка до стерилізації та придатна для локального нанесення безпосередньо на ділянки тканин, де шкірний покрив був порушений, причому лікарська сполука являє собою 1-(2-метилпропіл)-1Н-імідазо[4,5-с]хіноліни-4-амін (іміквімод), а композиція стерилізована опроміненням електронним пучком.
UAA200708769A 2006-07-31 2007-07-30 Стерильний склад модифікатора імунної відповіді та способи одержання зазначеного складу UA93496C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82087606P 2006-07-31 2006-07-31

Publications (1)

Publication Number Publication Date
UA93496C2 true UA93496C2 (uk) 2011-02-25

Family

ID=38617896

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200708769A UA93496C2 (uk) 2006-07-31 2007-07-30 Стерильний склад модифікатора імунної відповіді та способи одержання зазначеного складу

Country Status (24)

Country Link
US (1) US8124096B2 (uk)
EP (1) EP1891953B1 (uk)
AR (1) AR062121A1 (uk)
AT (1) ATE532511T1 (uk)
AU (1) AU2007279376B2 (uk)
CA (1) CA2659733A1 (uk)
CL (1) CL2007002228A1 (uk)
CY (1) CY1112264T1 (uk)
DK (1) DK1891953T3 (uk)
ES (1) ES2375744T3 (uk)
HR (1) HRP20120128T1 (uk)
IL (1) IL184652A (uk)
ME (1) MEP20608A (uk)
NO (1) NO338958B1 (uk)
PE (1) PE20080523A1 (uk)
PL (1) PL1891953T3 (uk)
PT (1) PT1891953E (uk)
RS (2) RS52120B (uk)
RU (1) RU2474425C2 (uk)
SI (1) SI1891953T1 (uk)
UA (1) UA93496C2 (uk)
UY (1) UY30513A1 (uk)
WO (1) WO2008016475A2 (uk)
ZA (1) ZA200900618B (uk)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078889B2 (en) 2009-07-13 2015-07-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US9271973B2 (en) 2008-08-18 2016-03-01 Medicis Pharmaceutical Corporation Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
KR101106812B1 (ko) * 2003-08-27 2012-01-19 쓰리엠 이노베이티브 프로퍼티즈 컴파니 아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린
JP5043435B2 (ja) 2003-10-03 2012-10-10 スリーエム イノベイティブ プロパティズ カンパニー アルコキシ置換イミダゾキノリン
SG149829A1 (en) 2003-10-03 2009-02-27 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
WO2005051317A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
WO2006083440A2 (en) 2004-12-30 2006-08-10 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US20080318998A1 (en) * 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
EP1845988A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
JP2008538203A (ja) * 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
EP1851224A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
WO2006091567A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2621831A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EP1948173B1 (en) 2005-11-04 2013-07-17 3M Innovative Properties Company Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
GB0715428D0 (en) * 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
SI2378876T1 (sl) 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
WO2012024284A1 (en) 2010-08-17 2012-02-23 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
CN103582496B (zh) 2011-06-03 2016-05-11 3M创新有限公司 具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
BR112013031039B1 (pt) 2011-06-03 2020-04-28 3M Innovative Properties Co compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
CN106029156A (zh) 2014-02-21 2016-10-12 阿瓦蒂姆技术股份有限公司 维护尿道导管的方法
US20160158393A1 (en) * 2014-02-21 2016-06-09 Avadim Technologies, Inc. Method for Improving Health Outcomes
MX2017006657A (es) 2014-11-19 2018-03-15 Avadim Tech Inc Método para la prevención y el tratamiento del acné.
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
WO2019123178A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CN109481674A (zh) * 2018-11-14 2019-03-19 大连亚维药业有限公司 一种生物无菌乳膏药物的生产方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US24906A (en) * 1859-07-26 Simeon goodfellow
IT610737A (uk) 1955-11-18 1900-01-01
US3700674A (en) 1969-04-30 1972-10-24 American Cyanamid Co 4-alkylamino-3-nitroquinolines
US4013665A (en) 1973-10-01 1977-03-22 Bristol-Myers Company Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines
US4052393A (en) 1975-11-03 1977-10-04 E. R. Squibb & Sons, Inc. 4-Substituted derivatives of pyrazolo [1,5-a]-quinoxaline-3-carboxylic acids and esters
US4191767A (en) 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines
US4197403A (en) 1977-01-07 1980-04-08 Westwood Pharmaceuticals Inc. 4-Aminosubstituted imidazo(1,2-A)quinoxalines
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
EP0107455B1 (en) 1982-10-18 1986-07-09 Pfizer Inc. Triazoloquinoxalines as antidepressants and antifatigue agents
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1248450A (en) 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
CA1263378A (en) 1985-01-08 1989-11-28 Robert James Alaimo Imidazo¬4,5-f|quinolines useful as immunomodulating agents
US4751087A (en) 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4908389A (en) 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
EP0375689B1 (en) 1987-06-01 1992-08-12 Warner-Lambert Company A pharmaceutical composition adapted for transdermal delivery of an opoid drug.
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
DK0872478T3 (da) 1991-03-01 2003-03-31 Minnesota Mining & Mfg Mellemprodukter til fremstilling af 1-substituerede, 2-substituerede 1H-imidazo[4,5-c]quinolin-4-aminer
DK0708772T3 (da) 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
DE69737935T2 (de) 1996-10-25 2008-04-03 Minnesota Mining And Manufacturing Co., St. Paul Die Immunantwort modifizierende Verbindung zur Behandlung von durch TH2 vermittelten und verwandten Krankheiten
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
EP0877089A1 (en) 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
SI1040112T1 (en) 1997-12-11 2005-02-28 Minnesota Mining And Manufacturing Company Imidazonaphthyridines and their use in inducing cytokine biosynthesis
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2002534377A (ja) 1999-01-08 2002-10-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節因子を用いて粘膜関連の病態を治療するための製剤および方法
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
RU2143900C1 (ru) * 1999-03-31 2000-01-10 Институт цитологии и генетики СО РАН Способ получения изониазида пролонгированного действия
DE19941509A1 (de) 1999-08-31 2001-03-29 Interconnectron Ges Fuer Ind S Rundsteckverbinder zur Herstellung elektrischer Leitungsverbindungen
US6464937B2 (en) * 2000-11-01 2002-10-15 Pml Microbiologicals, Inc. Ultrapure sterilization of microbiological test media by electron beam irradiation
US20030026794A1 (en) 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
NZ532769A (en) 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
US20060183767A1 (en) 2003-01-06 2006-08-17 Eugene Mandrea Methods of stimulating immune response in certain individuals
BRPI0408476A (pt) 2003-03-13 2006-04-04 3M Innovative Properties Co métodos para melhorar a qualidade da pele
AU2004268665A1 (en) 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1602365A1 (en) * 2004-03-03 2005-12-07 Switch Biotech Aktiengesellschaft Pharmaceutical composition for topical use in form of xerogels or films and methods for production
US20050201959A1 (en) 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
US20080193468A1 (en) 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9271973B2 (en) 2008-08-18 2016-03-01 Medicis Pharmaceutical Corporation Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US9078889B2 (en) 2009-07-13 2015-07-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US10238645B2 (en) 2009-07-13 2019-03-26 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US10918635B2 (en) 2009-07-13 2021-02-16 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US11850245B2 (en) 2009-07-13 2023-12-26 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts

Also Published As

Publication number Publication date
SI1891953T1 (sl) 2012-05-31
AU2007279376B2 (en) 2012-09-06
ATE532511T1 (de) 2011-11-15
ZA200900618B (en) 2010-03-31
RS52120B (en) 2012-08-31
IL184652A0 (en) 2008-01-20
MEP20608A (en) 2010-06-10
ES2375744T3 (es) 2012-03-05
CA2659733A1 (en) 2008-02-07
RU2007129104A (ru) 2009-02-10
CY1112264T1 (el) 2015-12-09
NO338958B1 (no) 2016-11-07
EP1891953B1 (en) 2011-11-09
UY30513A1 (es) 2008-02-29
WO2008016475A2 (en) 2008-02-07
NO20073913L (no) 2008-02-01
WO2008016475A3 (en) 2008-11-20
CL2007002228A1 (es) 2008-01-18
RS20070318A (en) 2009-05-06
PE20080523A1 (es) 2008-07-13
US8124096B2 (en) 2012-02-28
DK1891953T3 (da) 2012-02-27
AR062121A1 (es) 2008-10-15
PL1891953T3 (pl) 2012-04-30
PT1891953E (pt) 2012-01-24
AU2007279376A1 (en) 2008-02-07
US20100096287A1 (en) 2010-04-22
IL184652A (en) 2014-02-27
RU2474425C2 (ru) 2013-02-10
EP1891953A1 (en) 2008-02-27
HRP20120128T1 (hr) 2012-03-31

Similar Documents

Publication Publication Date Title
UA93496C2 (uk) Стерильний склад модифікатора імунної відповіді та способи одержання зазначеного складу
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
BRPI0514098A (pt) formulação farmacêutica
MX2011012122A (es) Derivados de tiofeno.
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
UA86595C2 (uk) Гамма-кристалічна форма гідрохлориду івабрадину, спосіб її одержання і фармацевтична композиція, яка її містить
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
BRPI0510719A (pt) derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
SG178975A1 (en) Indenone derivative and pharmaceutical composition comprising same
BRPI0908052A2 (pt) Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EA200900267A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ И СТЕРОИДОВ
ES2328496T3 (es) Compuestos de 1,4,8-triaza-espiro(4,5)decan-2-ona sustituidos.
BRPI0514250A (pt) uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamento
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds
MX2008011020A (es) Compuestos de receptor sigma.
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
TW200716618A (en) Chemical compounds
BR112012015170A8 (pt) Derivado de amino-heteroarila, composição farmacêutica, uso de um derivado de amino-heteroarila, e, método para tratamento de dor